Clari Vest Asset Management LLC Sage Therapeutics, Inc. Transaction History

Clari Vest Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$40.65 - $59.54 $113,698 - $166,533	-2,797 Reduced 16.57%	14,078 $661,000
Q1 2023 May 08, 2023	SELL	$37.27 - $46.57 $596 - $745	-16 Reduced 0.09%	16,875 $708,000
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $2,093 - $2,834	-65 Reduced 0.38%	16,891 $644,000
Q3 2022 Nov 10, 2022	SELL	$32.28 - $43.27 $172,504 - $231,234	-5,344 Reduced 23.96%	16,956 $664,000
Q2 2022 Aug 12, 2022	SELL	$27.52 - $37.99 $159,616 - $220,342	-5,800 Reduced 20.64%	22,300 $720,000
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $103,768 - $131,908	-2,800 Reduced 9.06%	28,100 $1.2 Million
Q3 2021 Nov 08, 2021	SELL	$40.26 - $57.37 $64,416 - $91,792	-1,600 Reduced 4.92%	30,900 $1.37 Million
Q2 2021 Aug 09, 2021	BUY	$54.88 - $79.29 $1.78 Million - $2.58 Million	32,500 New	32,500 $1.85 Million
Q2 2018 Aug 10, 2018	SELL	$140.36 - $175.76 $735,486 - $920,982	-5,240 Closed	0 $0
Q1 2018 May 08, 2018	BUY	$152.15 - $192.33 $15,215 - $19,233	100 Added 1.95%	5,240 $845,000
Q4 2017 Feb 13, 2018	BUY	$60.72 - $167.34 $312,100 - $860,127	5,140	5,140 $846,000

218

48.2M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $415M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Clari Vest Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Clari Vest Asset Management LLC with notifications on news.